Epidemiologic and Health Economic Evaluation of Cervical Cancer Screening in Rural China.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 May 2020
Historique:
received: 26 10 2019
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 3 2 2021
Statut: epublish

Résumé

Cervical cancer is preventable and curable by detected early and managed effectively. To explore the most economical and effective cervical cancer screening strategies would lay a solid foundation for reducing the health and economic burden of cervical cancer. A Markov model was established for a cohort of 100,000 female to simulate the natural history of cervical cancer. 18 screening strategies were estimated including careHPV, Thin prep cytologic (TCT), Visual inspection with acetic acid/ Lugol's iodine (VIA / VILI), careHPV in series with VIA / VILI, careHPV in series with TCT, three methods parallel connection every 1, 3, 5 years respectively. Model outcomes included cumulative risk of incidence and death of cervical cancer, quality-adjusted life years (QALYs), cost-effectiveness ratios (CERs), incremental cost-effectiveness ratios (ICERs), cost-utility ratios (CURs) and benefits. According to the results of epidemiological analysis, careHPV similar to the parallel connection every 1 year achieved highest epidemiological effects via reducing the cumulative risk of onset and death by more than 98 %. In health-economic terms, CER among all the screening strategies ranged from -756.34 to 113040.3 Yuan per year and CUR ranged from -169.91 to 11968.27 Yuan per QALY. The benefit ranged from -1629 to 996 Yuan. The incremental cost-effectiveness analysis showed that three methods in parallel every 1 year, TCT every 1 year, VIA/VILI every 1, 3, 5 years and careHPV every 5 years were dominant strategies. Considering the economic and health benefits of all the strategies, our results suggested careHPV every 3 or 5 years and VIA/VILI every 1 or 3 years eventually were more appropriate as screening methods in rural China.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer is preventable and curable by detected early and managed effectively. To explore the most economical and effective cervical cancer screening strategies would lay a solid foundation for reducing the health and economic burden of cervical cancer.
METHODS METHODS
A Markov model was established for a cohort of 100,000 female to simulate the natural history of cervical cancer. 18 screening strategies were estimated including careHPV, Thin prep cytologic (TCT), Visual inspection with acetic acid/ Lugol's iodine (VIA / VILI), careHPV in series with VIA / VILI, careHPV in series with TCT, three methods parallel connection every 1, 3, 5 years respectively. Model outcomes included cumulative risk of incidence and death of cervical cancer, quality-adjusted life years (QALYs), cost-effectiveness ratios (CERs), incremental cost-effectiveness ratios (ICERs), cost-utility ratios (CURs) and benefits.
RESULTS RESULTS
According to the results of epidemiological analysis, careHPV similar to the parallel connection every 1 year achieved highest epidemiological effects via reducing the cumulative risk of onset and death by more than 98 %. In health-economic terms, CER among all the screening strategies ranged from -756.34 to 113040.3 Yuan per year and CUR ranged from -169.91 to 11968.27 Yuan per QALY. The benefit ranged from -1629 to 996 Yuan. The incremental cost-effectiveness analysis showed that three methods in parallel every 1 year, TCT every 1 year, VIA/VILI every 1, 3, 5 years and careHPV every 5 years were dominant strategies.
CONCLUSION CONCLUSIONS
Considering the economic and health benefits of all the strategies, our results suggested careHPV every 3 or 5 years and VIA/VILI every 1 or 3 years eventually were more appropriate as screening methods in rural China.

Identifiants

pubmed: 32458639
doi: 10.31557/APJCP.2020.21.5.1317
pmc: PMC7541874
pii:
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1317-1325

Références

Int J Gynecol Cancer. 2014 Mar;24(3):576-85
pubmed: 24557438
Sex Transm Infect. 2017 Dec;93(S4):S36-S45
pubmed: 29223961
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Aug;27(4):273-6
pubmed: 24579473
Asian Pac J Cancer Prev. 2015;16(17):7401-7
pubmed: 26625735
J Low Genit Tract Dis. 2013 Jul;17(3):315-9
pubmed: 23422644
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Chin J Cancer Res. 2018 Feb;30(1):1-12
pubmed: 29545714
Lancet Oncol. 2008 Oct;9(10):929-36
pubmed: 18805733
BMC Cancer. 2011 Jun 13;11:239
pubmed: 21668946
Jpn J Clin Oncol. 2015 Jan;45(1):7-11
pubmed: 25398583
Asian Pac J Cancer Prev. 2015;16(5):1907-12
pubmed: 25773843
Int J Cancer. 2012 Dec 15;131(12):2929-38
pubmed: 22488743
J Cancer Res Clin Oncol. 2003 Dec;129(12):691-702
pubmed: 14557878
Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):221-32
pubmed: 22075441
Int J Cancer. 2004 Jul 20;110(6):907-13
pubmed: 15170675
Int J Gynaecol Obstet. 2016 Sep;134(3):239-46
pubmed: 27350227
Obstet Gynecol. 2008 Jan;111(1):167-77
pubmed: 18165406
Clin J Oncol Nurs. 2016 Feb;20(1):79-83
pubmed: 26800410
BMC Cancer. 2016 Feb 26;16:164
pubmed: 26919850
BMC Public Health. 2017 Jan 25;17(1):118
pubmed: 28122530

Auteurs

Fei Zhao (F)

West China School of Public Health and West Fourth Hospital, Sichuan University, Chengdu, China.

Ying Wen (Y)

West China School of Public Health and West Fourth Hospital, Sichuan University, Chengdu, China.
Department of Molecular Epidemiology, Shenzhen Center for Disease Control and Prevention, Shenzhen,China.

Yang Li (Y)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union M Medical College, Beijing, China.

Siyuan Tao (S)

West China School of Public Health and West Fourth Hospital, Sichuan University, Chengdu, China.

Li Ma (L)

Dalian Medical University, Dalian, China.

Yuqian Zhao (Y)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sichuan Cancer Hospital &Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science &Technology of China, Chengdu, China.

Le Dang (L)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Ying Wang (Y)

West China School of Public Health and West Fourth Hospital, Sichuan University, Chengdu, China.

Fanghui Zhao (F)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jinghe Lang (J)

Peking Union Medical college Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College(CAMS/PUMC), Beijing, China.

Youlin Qiao (Y)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Chun-Xia Yang (CX)

West China School of Public Health and West Fourth Hospital, Sichuan University, Chengdu, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH